Novavax Stock Pops After Pfizer Licensing Agreement

Core Viewpoint - Novavax Inc. has signed a licensing agreement with Pfizer for its Matrix-M adjuvant, valued at up to $500 million, which includes a $30 million upfront payment [1] Group 1: Stock Performance - Novavax shares have increased by 3.3%, trading at $8.27, and have risen 65% from a low of $5.01 on April 10 [1][2] - The stock reached its highest level since October after bouncing off support at the $6.50 level, indicating a potential upward trend [2] - If the current gains are maintained, it will mark the third gain in the last five trading sessions [2] Group 2: Analyst Ratings - The analyst community is divided, with five analysts rating Novavax as a "strong buy" while another five suggest a "hold" or worse [2] - Short interest in Novavax accounts for 36.9% of the available float, indicating a significant level of bearish sentiment among investors [2] Group 3: Options Trading Activity - Options traders have shown strong bullish sentiment, as evidenced by a 50-day call/put volume ratio of 29.67, the highest in the past year [3] - Novavax's Schaeffer's Volatility Index (SVI) stands at 57%, which is higher than only 18% of readings from the past year, suggesting that near-term options traders expect relatively low volatility [3]